Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

CMC Biologics and OncoSynergy Enter into Agreement

Published: Monday, December 23, 2013
Last Updated: Sunday, December 22, 2013
Bookmark and Share
Agreement to develop and manufacture material for IND enabling studies and phase I clinical trials.

CMC Biologics and OncoSynergy have announced that the two companies entered into an agreement for cell-line development, process development, analytical development and manufacturing of non-GMP material to enable early toxicology testing and cGMP material for IND enabling toxicology studies and Phase I clinical trials.

This work will advance OncoSynergy’s OS2966 monoclonal antibody program based on its “Targeted Synergy” approach - a transformative strategy allowing broad inhibition of multiple
fundamental cancer growth mechanisms with a single drug.

“We look forward to helping advance OncoSynergy’s OS2966 drug platform targeting cancers resistant to currently available therapies,” said Gustavo Mahler, Global Chief Operations Officer
of CMC Biologics. “This contract highlights CMC Biologics’ proven and trusted platform for monoclonal antibody development and manufacturing.”

The project will be executed by CMC Biologics at its Copenhagen development and manufacturing facility. OncoSynergy EU SAS in France will lead the project.

"We are impressed with CMC Biologics’ experience and technical competency in biopharmaceutical development and cGMP manufacturing," said OncoSynergy Co-Founder and CEO, Shawn Carbonell, MD, PhD.

Carbonell continued, “Choosing a partner who can provide a complete solution - from expression of the sequence of interest, to providing material suitable for clinical trials - was a critical decision as we advance our lead candidate. They have also shown flexibility to accommodate our unique program needs as a virtual startup company.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

CMC Biologics, IDT Biologika Collaborate
Company has announced the collaboration will provide an efficient solution for development and manufacture of ADCs.
Saturday, February 27, 2016
CMC Biologics and OncoSynergy Enter into an Agreement
Agreement for accelerated process development and GMP manufacture of an investigational drug to combat Ebola.
Friday, December 19, 2014
CMC Biologics Achieves Authorization for cGMP Commercial Manufacturing by DKMA
Copenhagen biopharmaceutical manufacturing facility expanded to support growing customer demand for clinical and commercial production.
Thursday, October 17, 2013
CMC Biologics Acquires XOMA’s Bay Area Manufacturing Facility
Expansion designed to further support growing customer demand for cGMP clinical and commercial biologics production.
Tuesday, August 07, 2012
Scientific News
Advanced Lymphoma in Remission After T-Cell Therapy
63% of trial participants who recieved two-drug combination chemo plus intermediate dose of engineered T cells went into complete remission.
New Treatment for Immune Cancers
Clinical trial shows new drug holds promise for treating advanced mastocytosis.
Sickle Cell Gene Therapy Passes Test
Researchers found a precision-engineered gene therapy virus reduced sickle-induced red-cell damage in mice with sickle cell disease.
Opening Door to Oesophageal Cancer Targeted Treatments
Scientists have discovered that oesophageal cancer can be classified into three different subtypes.
Inovio Launches Zika Vaccine Trial
Inovio launches Zika vaccine trial in midst of Puerto Rico epidemic to explore early signals of vaccine efficacy.
Vitamin C May Boost Leukemia Treatment
Studies show that supplementing an epigenetic cancer drug with vitamin C enhanced the drug's effectiveness.
New Hope for Zika Treatment Found in Large-Scale Screen of Existing Drugs
Johns Hopkins researchers join collaborative group to screen 6,000 existing drugs in hopes of finding treatments for Zika Virus infection
FINCH Filgotinib Phase 3 Program Initiated
Galapagos NV reports the initiation of the FINCH global Phase 3 program in rheumatoid arthritis patient populations.
Stem Cell Therapy Heals Injured Mouse Brain
A team of researchers has developed a therapeutic technique that dramatically increases the production of nerve cells in mice with stroke-induced brain damage.
Zika Vaccine Testing in Humans
The NAAID has initiated a clinical trail of a vaccine candidate for the prevention of the Zika virus infection.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!